Human target validation of phosphoinositide 3-kinase (PI3K)β: Effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 10, 2012, Pages 2127-2136

  Nylander, S ^a   Kull, B ^a   Bjorkman J A ^a   Ulvinge, J C ^a   Oakes, N ^a   Emanuelsson, B M ^a   Andersson, M ^a   Skarby T ^a   Inghardt, T ^a   Fjellstrom O ^a   Gustafsson, D ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Bleeding; Human; Insulin; PI3K ; Platelets; Thrombosis

Indexed keywords

AZD 6482; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; BLEEDING; BLEEDING TIME; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG TOLERABILITY; EX VIVO STUDY; GLUCOSE INFUSION; GLUCOSE TRANSPORT; HOMEOSTASIS; HUMAN; HUMAN CELL; HYPERINSULINEMIA; IC 50; IN VITRO STUDY; INFUSION RATE; INSULIN SENSITIVITY; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION;

ADIPOCYTES; ADOLESCENT; ADULT; ANIMALS; BLEEDING TIME; BLOOD PLATELETS; CELL LINE, TUMOR; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FIBRINOLYTIC AGENTS; GLUCOSE; HEMOSTASIS; HEMOSTATICS; HUMANS; INSULIN RESISTANCE; MALE; ORTHO-AMINOBENZOATES; PHOSPHORYLATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINONES; RATS; SIGNAL TRANSDUCTION; THROMBOSIS; TIME FACTORS; YOUNG ADULT;

EID: 84866876711     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04898.x     Document Type: Article

References (29)

1. Gratacap MP, Guillermet-Guibert J, Martin V, Chicanne G, Tronchère H, Gaits-Iacovoni F, Payrastre B. Regulation and roles of PI3Kβ, a major actor in platelet signaling and functions. Adv Enzyme Regul 2011; 51: 106-16.
2. Hawkins PT, Anderson KE, Davidson K, Stephens LR. Signalling through Class I PI3Ks in mammalian cells. Biochem Soc Trans 2006; 34: 647-62.
3. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006; 125: 733-47.
4. Chaussade C, Rewcastle GW, Kendall JD, Denny WA, Cho K, Grønning LM, Chong ML, Anagnostou SH, Jackson SP, Daniele N, Shepherd PR. Evidence for functional redundancy of class IA PI3K isoforms in insulin signaling. Biochem J 2007; 404: 449-58.
5. Ciraolo E, Iezzi M, Marone R, Marengo S, Curcio C, Costa C, Azzolino O, Gonella C, Rubinetto C, Wu H, Dastrù W, Martin EL, Silengo L, Altruda F, Turco E, Lanzetti L, Musiani P, Rückle T, Rommel C, Backer JM, et al. Phosphoinositide 3 kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. Sci Signal 2008; 1: ra3.
6. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008; 454: 776-9.
7. Wee S, Wiederschain D, Maira SM, Loo A, Miller C, de Beaumont R, Stegmeier F, Yao YM, Lengauer C. PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci USA 2008; 105: 13057-62.
8. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 2005; 11: 507-14.
9. Schoenwaelder SM, Ono A, Sturgeon S, Chan SM, Mangin P, Maxwell MJ, Turnbull S, Mulchandani M, Anderson K, Kauffenstein G, Rewcastle GW, Kendall J, Gachet C, Salem HH, Jackson SP. Identification of a unique co-operative phosphoinositide 3-kinase signaling mechanism regulating integrin alpha IIb beta 3 adhesive function in platelets. J Biol Chem 2007; 282: 28648-58.
10. Kim S, Mangin P, Dangelmaier C, Lillian R, Jackson SP, Daniel JL, Kunapuli SP. Role of phosphoinositide 3-kinase beta in glycoprotein VI-mediated Akt activation in platelets. J Biol Chem 2009; 284: 33763-72.
11. Gilio K, Munnix IC, Mangin P, Cosemans JM, Feijge MA, van der Meijden PE, Olieslagers S, Chrzanowska-Wodnicka MB, Lillian R, Schoenwaelder S, Koyasu S, Sage SO, Jackson SP, Heemskerk JW. Non-redundant roles of phosphoinositide 3-kinase isoforms alpha and beta in glycoprotein VI-induced platelet signaling and thrombus formation. J Biol Chem 2009; 284: 33750-62.
12. Canobbio I, Stefanini L, Cipolla L, Ciraolo E, Gruppi C, Balduini C, Hirsch E, Torti M. Genetic evidence for a predominant role of PI3Kbeta catalytic activity in ITAM- and integrin-mediated signaling in platelets. Blood 2009; 114: 2193-6.
13. Garcia A, Kim S, Bhavaraju K, Schoenwaelder SM, Kunapuli SP. Role of phosphoinositide 3-kinase beta in platelet aggregation and thromboxane A2 generation mediated by Gi signaling pathways. Biochem J 2010; 429: 369-77.
14. Martin V, Guillermet-Guibert J, Chicanne G, Cabou C, Jandrot-Perrus M, Plantavid M, Vanhaesebroeck B, Payrastre B, Gratacap MP. Deletion of the p110beta isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo. Blood 2010; 115: 2008-13.
15. Sturgeon SA, Jones C, Angus JA, Wright CE. Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat. Eur J Pharmacol 2008; 587: 209-15.
16. Jackson SP, Robertson AD, Kenche V, Thompson P, Prabaharan H, Anderson K, Abbott B, Goncalves I, Nesbitt W, Schoenwaelder S, Saylik D. Preparation of morpholinyl- and pyridinyl-substituted heterobicyclic ketones as selective inhibitors of phosphoinositide 3-kinase β for use against thrombosis. PCT Int Appl WO2004016607, 2004.
17. Ni J, Liu Q, Xie S, Carlson C, Von T, Vogel K, Riddle S, Benes C, Eck M, Roberts T, Gray N, Zhao J. Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110β as a Potential Anticancer Agent. Cancer Discov 2012; 2: 425-33.
18. Fjellström O, Gustafsson D, Jackson S, Lindberg JÅ. Preparation of enantiomerically pure (-)2-[1-(7-Me-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1, 2-a]pyrimidin-9-yl)ethylamino]benzoic acid, its use as a selective PI3-kinase β inhibitor for therapy. PCT Int Appl 2009.WO2009093972.
19. Robertson AD, Jackson S, Kenche V, Yaip C, Parbaharan H, Thompson P. Preparation and formulation of morpholino-substituted heterocycles as phosphoinositide 3-kinase inhibitors for therapeutic use. PCT Int Appl 2001WO2001053266.
20. Bengtsson M, Larsson J, Nikitidis G, Storm P, Bailey JP, Griffen EJ, Arnould J-C, Bird T, Geoffrey C. Preparation of 5-heteroaryl thiazoles and their use as phosphoinositide 3-kinase (PI3K) inhibitors. PCT Int Appl 2006. WO2006051270 (2006).
21. Folts J. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation 1991; 6(Suppl.): IV3-14.
22. van Giezen JJ, Berntsson P, Zachrisson H, Björkman JA. Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. Thromb Res 2009; 124: 565-71.
23. Ljung B, Bamberg K, Dahllöf B, Kjellstedt A, Oakes ND, Östling J, Svensson L, Camejo G. AZ 242, a novel PPARα/γ agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J Lipid Res 2002; 43: 1855-63.
24. Wåhlander K, Eriksson-Lepkowska M, Nyström P, Eriksson UG, Sarich TC, Badimon JJ, Kalies I, Elg M, Bylock A. Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model. Thromb Haemost 2006; 95: 447-53.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
26. Giordanetto F, Kull B, Dellsen A. Discovery of novel class 1 phosphatidylinositide 3-kinases (PI3K) fragment inhibitors through structure-based virtual screening. Bioorg Med Chem Lett 2011; 21: 829-35.
27. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003; 3: 155-68.
28. Williams O, Houseman BT, Kunkel EJ, Aizenstein B, Hoffman R, Knight ZA, Shokat KM. Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: a prototype for new anti-inflammatory drugs. Chem Biol 2010; 17: 123-34.
29. Bird JE, Smith PL, Bostwick JS, Shipkova P, Schumacher WA. Bleeding response induced by anti-thrombotic doses of a phosphoinositide 3-kinase (PI3K)-β inhibitor in mice. Thromb Res 2011; 127: 560-4.